JNJ Crushes Earnings with Record Sales and Strong Growth

Johnson & Johnson (JNJ) has delivered record quarterly results, outperforming its peers in the process. The company's shares have gained over 25% so far this year, with recent earnings driving positive momentum post-report.

The pharmaceutical giant's sales reached a new high of $25.3 billion, reflecting a 6.6% year-over-year increase. This growth has also led to an upward revision in both its current fiscal year sales and adjusted EPS guidance.

JNJ is on track to meet its target of over $100 billion in annual revenue for the first time in its history. The company's consistent history of increased payouts makes it a prime consideration for investors seeking dividend-paying stocks with a proven track record.